Healthcare Industry News: chronic myelogenous leukemia
News Release - February 15, 2007
INNOVIVE Pharmaceuticals Appoints Angelo De Caro to Its Board of Directors and Audit Committee
NEW YORK, Feb. 15 (HSMN NewsFeed) -- INNOVIVE Pharmaceuticals, Inc. (OTC Bulletin Board: IVPH ) today announced that Angelo De Caro has been appointed to serve on the Company's Board of Directors and Audit Committee. Mr. De Caro brings to the Company more than four decades of experience in finance and operations. He has served as Chairman and CEO of Patriot National Bancorp, Inc., since 2001 and as a Director of the company since 1999. Additionally, during more than 16 years with Goldman Sachs & Co., he oversaw various operations departments including finance and taxation, as well as audit and risk management functions. He served as General Partner and Senior Financial Officer at Goldman Sachs for more than 10 years and was a member of the Executive Committee of the company's Swiss Private Bank.In addition to his tenures with Patriot National Bancorp and Goldman Sachs, Mr. De Caro served as Vice President and Senior Financial Officer at Loeb Rhoades, Inc., an investment banking firm. He was educated at Long Island University and holds an M.S. in accounting and taxation, and a B.S. in accounting.
About INNOVIVE Pharmaceuticals
INNOVIVE Pharmaceuticals, Inc. acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. The company has four drug programs in clinical development: Tamibarotene, INNO-406, INNO-206, and INNO-305, for the treatment of acute promyelocytic leukemia, chronic myelogenous leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information, visit www.innovivepharma.com.
Source: INNOVIVE Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
